

Communication

Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides

Kariem Ahmed, YOSHITSUGU AOKI, Taeyoung Koo, Graham McClorey, Leif Benner, Anna Coenen-Stass, Liz O'Donovan, Taavi Lehto, Antonio Garciguerra, Joel Zacharias Nordin, Amer F. Saleh, Mark A. Behlke, John Morris, Aurelie Goyenvalle, Branislav Dugovic, Christian Joerg Leumann, Siamon Gordon, Michael J. Gait, Samir El-Andaloussi, and Matthew J.A. Wood

Nano Lett., **Just Accepted Manuscript** • DOI: 10.1021/acs.nanolett.5b00490 • Publication Date (Web): 04 Jun 2015

Downloaded from <http://pubs.acs.org> on June 10, 2015

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



1
2
3 **Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic**
4 **antisense oligonucleotides**
5
6
7
8
9

10 Kariem Ezzat ^{1*}, Yoshitsugu Aoki ^{1,11*}, Taeyoung Koo ^{1,2,3}, Graham McClorey¹, Leif Benner ¹,
11 Anna Coenen-Stass ¹, Liz O'Donovan ⁴, Taavi Lehto ⁵, Antonio Garcia-Guerra⁶, Joel Nordin⁵,
12 Amer F. Saleh ⁴, Mark Behlke⁷, John Morris ¹, Aurelie Goyenvalle⁸, Branislav Dugovic⁹,
13 Christian Leumann⁹, Siamon Gordon¹⁰, Michael J. Gait⁴, Samir El-Andaloussi^{1,5} and Matthew
14 JA Wood ¹.
15
16
17
18
19
20
21
22
23
24
25

26 ¹Department of Physiology, Anatomy and Genetics, University of Oxford, OX13QX, Oxford,
27 UK
28
29
30

31 ²Center for Genome Engineering, Institute for Basic Science, Seoul, South Korea
32
33

34 ³Functional Genomics, University of Science and Technology, Daejeon, South Korea
35
36

37 ⁴Medical Research Council Laboratory of Molecular Biology, Cambridge, CB2 0QH, UK
38
39

40 ⁵Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden
41
42
43

44 ⁶Clarendon Laboratory, Department of Physics, University of Oxford, OX13PU, Oxford, UK
45
46
47

48 ⁷Integrated DNA Technologies (IDT), Coralville, Iowa, USA
49
50

51 ⁸Université de Versailles Saint Quentin, Montigny le Bretonneux, France
52
53
54

55 ⁹Department of Chemistry & Biochemistry, University of Bern, Bern, Switzerland
56
57
58
59
60

1
2
3 ¹⁰Sir William Dunn School of Pathology, University of Oxford, OX1 3RE, Oxford, UK
4
5

6
7 ¹¹Department of Molecular Therapy, National Institute of Neuroscience, National Center of
8
9 Neurology and Psychiatry (NCNP), Tokyo, Japan
10
11

12
13
14
15 *These authors contributed equally to this work.
16

17 Correspondence should be addressed to: matthew.wood@dpag.ox.ac.uk
18
19
20
21
22
23

24 **Abstract**

25
26 Antisense oligonucleotides (ASOs) have the potential to revolutionize medicine due to their
27 ability to manipulate gene function for therapeutic purposes. ASOs are chemically modified
28 and/or incorporated within nanoparticles to enhance their stability and cellular uptake, however,
29 a major challenge is the poor understanding of their uptake mechanisms, which would facilitate
30 improved ASO designs with enhanced activity and reduced toxicity. Here, we study the uptake
31 mechanism of three therapeutically relevant ASOs (peptide-conjugated phosphorodiamidate
32 morpholino (PPMO), 2'-O-methyl phosphorothioate (2'OMe) and phosphorothioated tricyclo
33 DNA (tcDNA) that have been optimized to induce exon skipping in models of Duchenne
34 muscular dystrophy (DMD). We show that PPMO and tcDNA have high propensity to
35 spontaneously self-assemble into nanoparticles. PPMO forms micelles of defined size and their
36 net charge (zeta potential) is dependent on the medium and concentration. In biomimetic
37 conditions and at low concentrations, PPMO obtains net negative charge and its uptake is
38 mediated by class A scavenger receptor subtypes (SCARAs) as shown by competitive inhibition
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and RNAi silencing experiments *in vitro*. *In vivo*, the activity of PPMO was significantly
4
5 decreased in SCARA1 knock-out mice compared to wild-type animals. Additionally, we show
6
7 that SCARA1 is involved in the uptake of tcDNA and 2'OMe as shown by competitive
8
9 inhibition and co-localization experiments. Surface plasmon resonance binding analysis to
10
11 SCARA1 demonstrated that PPMO and tcDNA have higher binding profiles to the receptor
12
13 compared to 2'OMe. These results demonstrate receptor-mediated uptake for a range of
14
15 therapeutic ASO chemistries, a mechanism that is dependent on their self-assembly into
16
17 nanoparticles.
18
19
20
21
22
23

24 **Key words:** Antisense oligonucleotides, self-assembly, nanoparticles, scavenger receptors,
25
26 uptake mechanism, delivery
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Antisense oligonucleotides (ASOs) can be designed to target DNA and RNA in a sequence-
4 specific manner to stop, alter or induce particular gene functions. Thus, they have emerged as a
5 very promising new class of therapeutics that can target disease pathophysiology at the
6 molecular genetic level with high specificity. One of the most advanced applications of ASOs is
7 their use for manipulation of gene function through splice switching. ASOs can switch splicing
8 patterns through sequence-specific targeting of pre-mRNA elements involved in exon
9 recognition and/or consensus splice sites in a sequence-specific manner ¹. This approach has
10 been investigated as potential treatments for different types of muscular dystrophies, especially
11 Duchenne muscular dystrophy (DMD), where ASOs have been extensively tested in disease
12 models and are currently being evaluated in several clinical trials ^{2,3}. DMD is caused by loss of
13 function of the *DMD* gene due to deletions and/or mutations that cause the generation of
14 premature termination codons and/or out-of-frame transcripts ⁴. Targeting of splice sites or
15 putative exon splicing enhancers with ASOs can induce the removal of exons from the mature
16 *DMD* transcript such that a nonsense mutation is bypassed, or alternately removal of exons
17 around a genomic deletion can restore the mRNA reading frame.

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Chemical modifications are introduced into ASOs to enhance their stability against nucleases and to prevent immune stimulation ⁵. Despite the promising results of the ongoing trials using ASOs, major scientific challenges remain. The principle limitation of ASOs is their poor cellular uptake due to their large molecular weight and mostly highly charged nature. Paradoxically, in practice, ASO uptake is dramatically enhanced when they are incorporated with nanoparticles that are even larger in size and much richer in charge. Most transfection reagents and ASO delivery systems rely on complexation or loading ASOs into nanoparticulate vectors ⁶. Moreover, under certain conditions, naked ASOs of different chemistries are taken up by cells without the need

1
2
3 for transfection reagents in a process termed “gymnosis” via an unknown mechanism ⁷. Thus,
4 understanding the uptake mechanism and resolving these seemingly paradoxical observations is
5 very important for the clinical development of ASOs. Here we study the uptake mechanism of
6 three ASO compounds of different chemistries that have been optimized for skipping of exon 23
7 in preclinical or clinical studies of DMD.
8

9
10 The first compound is from the peptide- morpholino family (PPMOs), which comprises a cell-
11 penetrating peptide (CPP) attached to phosphorodiamidate morpholino oligomer; PMO ⁸. PMOs
12 possess a morpholino moiety instead of the ribose moiety and the backbone phosphodiester
13 linkages are replaced with uncharged phosphorodiamidate linkages. CPPs are short cationic
14 peptides that enhance the uptake of the PMO into cells ⁸. Here, we mainly use the B-peptide
15 conjugated PMO (B-PMO), a classical PPMO example, as our model ⁹. The second ASO is
16 from the second generation of chemically modified RNAs; phosphorothioate 2'OMe. The 2'OH
17 is replaced by a 2'OMe group and the phosphodiester linkages in the backbone are replaced by
18 the more stable phosphorothioate linkages ⁵. The third ASO is from the recently developed
19 family of tricyclo DNA (tcDNA). TcDNA has three additional C-atoms between C5' and C3'
20 which increase both the affinity and hydrophobicity of the molecule together with a
21 phosphorothioate backbone ¹⁰. Both 2'OMe and tcDNA chemistries have been shown to be taken
22 up by cells via gymnosis^{7,11}. All three molecules have been extensively tested in the well-
23 established *mdx* mouse model for DMD, which carries a nonsense mutation in exon 23 of the
24 *Dmd* gene. Of the three ASO classes, PPMOs are the most potent, achieving high levels of exon
25 skipping in different skeletal muscles at doses as low as 6 mg/kg ^{9,12}. TcDNA is the second most
26 potent chemistry tested here, with a superior activity over 2'OMe when administered at a dose of
27 200 mg/kg demonstrating effective exon skipping even in the brain ¹³.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Recently, we have demonstrated that a class of pattern recognition receptors (PRRs), namely
4 scavenger receptors (SRs), is involved in the uptake of certain CPPs when complexed with ASOs
5
6
7
8¹⁴. SRs are a large family of PRRs that are involved in the uptake of pathogen associated
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Recently, we have demonstrated that a class of pattern recognition receptors (PRRs), namely scavenger receptors (SRs), is involved in the uptake of certain CPPs when complexed with ASOs¹⁴. SRs are a large family of PRRs that are involved in the uptake of pathogen associated molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs) and play important functions in innate immunity and homeostasis¹⁵. They are subdivided into several classes, from A to I, which are structurally diverse but functionally similar in their ability to bind polyanionic (negatively charged) particulate substrates^{15,16}. The vast array of their ligands include: oxidized low density lipoprotein (oxLDL), acetylated LDL (acLDL), apoptotic cells, *Staphylococcus aureus* bacteria, HCV virus, lipopolysaccharide (LPS), PrP¹⁰⁶⁻¹²⁶ prion protein, viral RNA and different types of synthetic nanoparticles^{15,17,18}. Little is known about the structural features that are responsible for the promiscuous binding of SRs to negatively charged ligands; however, it is hypothesized that the surfaces that are engaged in ligand binding are similar in terms of shape and charge distribution, displaying clusters of cationic residues (cationic patches)¹⁵. Additionally, due to their observed low specificity and functional overlap, they are thought to function in the form of heteromultimeric receptor complexes (signalosomes) that comprise SRs and other co-receptors¹⁵. SRs are highly expressed in professional immune cells such as macrophages, but have also been shown to be expressed other cell types including smooth muscle cells, endothelial cells, fibroblasts, splenic dendritic cells, and epithelial cells¹⁹. Class A SRs (SCARAs) are among the most extensively studied SRs and are characterized structurally by their collagenous domains²⁰. SCARAs have different subtypes, including SCARA1 (SR-AI), SCARA2 (MARCO), SCARA3, SCARA4 (Colec12), and SCARA5, among which SCARA3 and SCARA5 have been shown earlier to be involved in uptake of CPP-ASO nanocomplexes¹⁴.

1
2
3 Here we study the effects of the physicochemical properties of the three different ASO
4 compounds (PPMO, phosphorothioate 2'OMe, phosphorothioate tcDNA) used for the treatment
5 of DMD and the role of SRs in their uptake, especially in muscle cells. We hypothesize that
6 variation in ASO activity is due to their physicochemical properties modulated by their ability to
7 self-assemble and to bind to SRs.
8
9
10
11
12
13

14 15 16 17 18 **RESULTS AND DISCUSSION**

19 20 **PPMO and tcDNA have high propensity to spontaneously self-assemble into nanoparticles.**

21 Physicochemical properties including particle size and charge are important determinants for
22 uptake of drug delivery systems. Recently, using transmission electron microscopy (TEM) and
23 nanoparticle tracking analysis, we found that tcDNA has a higher propensity to self-assemble
24 into nanoparticles compared to 2'OMe¹³. To investigate this further in comparison to the PPMO
25 chemistry we used dynamic light scattering (DLS). In accordance with our previous
26 observations, the predominant peak in the tcDNA sample was a broad particulate peak (Fig.
27 1A.). For PPMO, there were two peaks, one for singular molecules and one representing a
28 particulate population. However, for 2'OMe, the predominant peak was of singular molecules at
29 around 2 nm together with another particulate peak of much less intensity (Fig. 1A.).
30 Comparatively, these results show that both tcDNA and PPMO have a higher propensity to form
31 nanoparticles than 2'OMe. In order to make sure that this property of self-assembly is retained in
32 physiological conditions; we repeated the DLS measurements after incubation with physiological
33 concentrations of albumin solution in PBS for 1h at 37 °C. Albumin is the most abundant serum
34 protein representing up to 50% of total serum protein²¹. While it is difficult to run DLS in the
35 presence of full serum due to high background from diverse proteins, a simplified albumin based
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 model generates one distinct peak of albumin around 4 nm, which also acts as an internal
4 standard. Importantly, in this model, only tcDNA and PPMO were able to display high intensity
5 particulate peaks, while 2'OMe failed to do so (Fig. S1 A). To test full serum conditions on these
6 ASOs, fluorescently labelled tcDNA and PPMO were incubated with full serum for 1h at 37 °C,
7 and subsequently fractionated using a continuous sucrose gradient. The fraction with the highest
8 fluorescence signal was visualized via fluorescence microscopy. Densely bright particulate
9 structures were observed for tcDNA and PPMO under these conditions, showing that the process
10 of self-assembly into nanoparticles is maintained in physiological conditions and in the presence
11 of serum proteins (Fig. S1 B).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **Amphipathic PPMO forms micelles.** To further investigate the nanoparticles formed by the
28 PPMO, we used TEM visualization, as used previously for tcDNA and 2'OMe. PPMOs formed
29 well-defined nanoparticles with a diameter ranging between 30 and 90 nm (Fig. 1B). We
30 speculated that this spontaneous nanoparticle formation is due to the amphipathicity of the
31 PPMO structure that leads to self-assembly into micelles. The PPMO molecule is composed of a
32 relatively hydrophobic PMO portion and a very hydrophilic CPP that harbors multiple positive
33 charges, a structure susceptible to micelle formation. In fact, PMOs are among the most
34 hydrophobic ASO chemistries available. A PMO adenosine monomer has an octanol-water
35 partition coefficient (log P) of -2.72, while the log P for an adenosine nucleotide of the 2'OMe
36 chemistry is -4.15, -4.39 for locked nucleic acid (LNA), and -3.43 for peptide nucleic acid (PNA)
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

8

1
2
3 assemble into micelles in the bulk of the dispersion medium²³. Dyes such as eosin, rhodamine
4 and Sudan red are known to show a shift in the wavelength maximum (λ max) due to the
5 presence of micelles²³. Here, we used eosin Y which has wavelength maximum at 518 nm in
6 water; however, the presence of micelles increases its absorbance at 542 nm. CMC can be
7 determined by plotting the change in absorbance of the micellized dye at a fixed wavelength
8 (542 nm) against surfactant concentration. The linear portion near the inflection point is
9 extrapolated to intersect with the absorbance of the dye in the absence of any surfactant
10 (represented by the horizontal line in Fig. 1C.), and this concentration is the CMC²³. PPMO
11 behaviour was typical surfactant behaviour with a CMC of about 1.4 μ M. The PPMO probably
12 behaves similarly to multi-head-group surfactants; however, the complexity of the structure due
13 to the presence of an atypical hydrophobic tail (the PMO in this case) and up to 10 charges might
14 require the development of specific models to understand this process.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **PPMO charge reversal in biomimetic conditions.** The net charge of a nanoparticle is a
35 function of pH and the concentration of counterions in the medium. Thus, it is important to study
36 the properties of therapeutic compounds in biomimetic conditions in terms of pH or isotonicity
37 where their properties at these conditions are more relevant to their biological activity. We have
38 previously demonstrated that certain CPPs, such as PF14 which is used for ASO delivery via
39 non-covalent complexation, change their zeta potential according to the dispersion medium¹⁴.
40 To determine if the same is true for the self-assembled nanoparticles of PPMO, we measured the
41 zeta potential in different conditions. Interestingly, PPMOs displayed the same pattern, having a
42 positive zeta potential (10 ± 2.70) in water while changing into negative values in PBS ($-1.21 \pm$
43 0.63) and serum-free medium (-3.48 ± 2.31) due to the change in pH and high salt concentration.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Surprisingly, this charge reversal was also concentration dependent as demonstrated by gel
4 mobility shift assay (Fig. 1D). At high concentrations (50 μM), PPMO migrates towards the
5 cathode, indicating a net positive charge, but as the concentration gets lower, the migration
6 pattern shifts towards the anode indicating a net negative charge in a clear visualization of the
7 charge reversal phenomenon. These observations highlight the importance of the presence and
8 concentration of counterions in the solution. An important parameter to consider here is ξ , which
9 is the molar concentration ratio of counterions to surfactant ²⁴. When ξ increases, more
10 counterions bind to the micellar surface changing its net charge and this explains the
11 concentration dependent charge reversal. At higher PPMO concentrations ξ is low; hence, there
12 are not enough counterions in the running buffer to shield and reverse the exposed cationic
13 groups on the micellar surface; and thus, migration occurs towards the cathode. As the PPMO
14 concentration is decreased, the ξ ratio changed in favor of the concentration of counterions in the
15 running buffer enabling shielding and reversal of the net surface charge and migration to the
16 opposite pole. The same effect can be replicated by keeping the PPMO concentration constant
17 while changing the concentration of the counterions. When using TBE as a running buffer with
18 equimolar concentrations of the cationic basic species (Tris base) and the anionic acidic species
19 (boric acid), PPMO migration pattern can be seen to be divided between both the anode and the
20 cathode (Fig. S1 C). Interestingly, when using unbalanced TBE with excess basic species, the
21 migration pattern shifts towards the cathode indicating net positive charge, and the opposite takes
22 place upon using TBE with excess boric acid. This further supports our hypothesis that the net
23 charge of the PPMO depends on the delicate balance between the concentration of the PPMO
24 and the concentration of the counterions available in the medium.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Class A scavenger receptors are involved in PPMO uptake.** As aforementioned, we have
4 shown previously that the uptake of certain CPP complexes with ASOs is mediated by class A
5 scavenger receptor subtypes (SCARAs)¹⁴. To determine whether the change in charge of the
6 PPMO also mediates uptake through SCARAs, we tested the effects of SCARA ligands on the
7 PPMO splice-switching activity in the C2C12 muscle cell line. Fucoidin sulfate and dextran
8 sulfate are well-known SCARA ligands, and chondroitin sulfate is a chemically related molecule
9 but not a specific ligand; and thus serves as a negative control. Cells were treated with the
10 ligands or the control for 1h before treatment with the PPMO for 4 h, after which the medium
11 was changed and cells were incubated for 20 h. Both fucoidin sulfate and dextran sulfate
12 completely inhibited the splice-switching activity of the PPMO while chondroitin sulfate had no
13 effect (Fig. 2A). This competitive inhibition demonstrates the involvement of SCARAs in the
14 uptake and activity of PPMO.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 Moreover, several SCARA subtypes were expressed in the C2C12 murine myoblast cell line,
32 including SCARA1, 3, 4 (COLEC12) and 5 (Suppl. Fig. S2A). We next tested the effect of
33 silencing the expressed SCARA subtypes on PPMO activity. Upon using an siRNA cocktail
34 against all the expressed SCARA subtypes (1, 3, 4 and 5), the splice-switching activity of PPMO
35 was significantly reduced (Fig. 2B). We have recently demonstrated that the uptake and activity
36 of PPMOs was higher in differentiated myotubes compared to undifferentiated myoblasts both in
37 C2C12²⁵ and H2k *mdx* cell-lines²⁶, both of which represent common models to study muscle
38 differentiation. Interestingly, the expression of SCARA subtypes increases significantly
39 throughout the course of differentiation of both cell lines, which correlates closely with the
40 observed difference in PPMO uptake and activity (Fig. S2). Additionally, we performed TEM
41 and SCARA inhibition analysis to ensure that this PPMO (Pip6a-PMO) behaves similarly to the
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 model PPMO we are testing here (B-PMO). Pip6a peptide design is broadly similar to the B-
4 peptide but with the inclusion of a YQFLI core motif within the arginine rich sequence ²⁷. This
5 change enhanced its splice-switching activity *in vivo* especially in the heart; however, the cause
6 of this enhanced activity was not known. Here we show that Pip6a-PMO, similar to the B-PMO,
7 spontaneously forms nanoparticles that can be visualized via TEM and that its uptake is
8 significantly inhibited in the presence of SR ligands (Fig. S3). Interestingly, Pip6a-PMO
9 nanoparticles are smaller than B-PMO nanoparticles; a property that may contribute to its
10 enhanced biodistribution profile. Importantly, when injected *in vivo* in SCARA1 knock-out mice
11 ²⁸, the activity of Pip6a-PMO was significantly reduced in the diaphragm and heart compared to
12 wild-type (WT) mice (Fig. 2C). This demonstrates that the SR dependent interactions observed
13 *in vitro* also contribute to the biological activity of PPMOs *in vivo*. This does not exclude
14 however the involvement of other receptor subtypes (SCARA3,4 and 5) and other SR classes in
15 this process. The residual activity in the diaphragm and non-significant differences in tibialis
16 anterior (TA) might very likely be due to compensation and differential expression of other SRs
17 that are not altered in their expression in this model.

18
19 It is important to note that these observations for PPMOs could have more general implications
20 on understanding the mechanism of action of both CPPs and antimicrobial peptides (AMPs).
21 Several secondary amphipathic CPPs are known to self-assemble into nanoparticles ²⁹.
22 Furthermore, Kohno et al. ³⁰ have recently shown that the uptake of an antimicrobial peptide
23 (K8L9) at subcytotoxic concentrations is mediated by neuropilin-1 and low-density lipoprotein-
24 related protein receptor 1 (LRP1), a receptor with scavenger like properties. Moreover, using
25 siRNA screens, Kondo et al. ³¹ demonstrated the involvement of M160 (CD163L1; scavenger
26 receptor cysteine-rich type I) in the uptake of a tumor homing CPP (CPP44). This shows that the
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 phenomena of self-assembly and SR interaction are more general and that several SR receptor
4 classes might be involved in the CPP/AMP mechanism of action; however, the details of their
5 complimentary, synergistic or compensatory mechanisms require further studies. Additionally,
6 the observation that net charge is dependent on concentration might explain different
7 mechanisms of activity for CPPs and/or AMPs. At low concentrations, when there are sufficient
8 counterions to shield and reverse the positive charge, receptor-mediated uptake might be the
9 predominant mechanism of action. However, at high concentrations, when the net charge is
10 positive, direct membrane interactions might predominate; which could explain lytic and toxic
11 effects at such concentrations.
12
13
14
15
16
17
18
19
20
21
22
23

24
25
26 **Varied involvement of SRs in the uptake of PPMO, tcDNA and 2'OMe chemistries.** To
27 determine the involvement of SRs in the gymnotic uptake of the other ASO chemistries we
28 tested the effect of several SR ligands on the uptake of naked tcDNA and 2'OMe. The uptake of
29 FITC-tcDNA and FITC-2'OMe was monitored in the presence of polyinosinic acid (poly I),
30 polycytidylic acid (poly C), fucoidin sulfate, dextran sulfate and chondroitin sulfate. While
31 fucoidin and dextran sulfates are more specific for SCARAs, poly I is more general as it also
32 targets class C (SR-CI), class E (ORL-1/Lox-1) and class F (SREC) SRs³² in addition to other
33 receptors with scavenger properties such as Mac1³³ and nucleolin which binds quadruplex DNA
34 structures^{34,35}. Poly C serves as the control for poly I. The uptake of tcDNA and 2'OMe was
35 only partially inhibited in the presence of fucoidin and dextran sulfates, but almost completely
36 inhibited in the presence of poly I (93.6% and 89.0% respectively) (Fig. 3) demonstrating the
37 involvement of SCARAs together with other poly I sensitive SRs in the uptake, probably in
38 heteromultimeric signalosome complexes. SRs have been previously suggested to be involved in
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the uptake of negatively charged ASOs ³⁶⁻³⁹, and it has been shown that the formation of
4
5 multimers or the capacity to form G-quadruplexes enhance the uptake and activity of naked
6
7 ASOs ⁴⁰⁻⁴². This aggregation was also shown to enhance binding to SRs ^{43,44}. Thus, it is feasible
8
9 to speculate that the superior activity of tcDNA is related to its propensity to self-assemble into
10
11 nanoparticles mediating better SR interaction and subsequent cytotxic uptake. Indeed, we
12
13 observed that the extent of uptake of fluorescently labelled tcDNA is significantly higher than
14
15 that of 2'OMe despite having similar biological activity upon lipofection (Fig. S4). Equivalent
16
17 biological activity using lipofection was also demonstrated using sequences targeting exon 51
18
19 (Fig. S4D). This shows that despite other factors that might contribute to the superior activity of
20
21 tcDNA (mRNA binding for example), a higher uptake profile due to higher propensity to form
22
23 nanoparticles significantly contributes to this increased activity. This is more evident in the case
24
25 of PPMO, which displays several folds higher uptake than the other two chemistries (Fig. S4).
26
27 Furthermore, we studied the effect of other factors on the uptake of the ASOs. Incubation at 4 °C
28
29 significantly reduced the uptake of all the chemistries indicating the involvement of an active,
30
31 energy-dependent mechanism of uptake (Fig S4). Incubation in the presence of serum on the
32
33 other hand had only a small negative effect on uptake (Fig. S4), which might be due to the high
34
35 stability of these heavily chemically modified ASOs.
36
37
38
39
40
41
42

43 The mechanism of spontaneous tcDNA self-assembly is not well understood. While tcDNA
44
45 lacks the dichotomy of structure of the PPMO, the three additional C-atoms increase the
46
47 hydrophobicity of the molecule. We speculate that this increased hydrophobicity might impart
48
49 secondary amphipathic properties on the structure enabling self-assembly via mechanisms
50
51 resembling the self-assembly of secondary amphipathic peptides ²⁹. Alternatively, the extra rings
52
53 in the tcDNA might facilitate stacking and generation of structures resembling poly-G aggregates
54
55
56
57
58
59
60

1
2
3 that were seen to enhance the uptake of ASOs and binding to SRs⁴¹⁻⁴⁴. Structural and molecular
4 modeling studies are underway to unravel the mechanism of tcDNA self-assembly.
5
6
7
8
9

10 **Co-localization and SCARA1 binding.** To demonstrate direct association between ASOs and
11 receptor we performed co-localization experiments and Surface Plasmon Resonance (SPR)
12 binding analysis. Immunocytochemical analysis using an anti-SCARA1 antibody showed co-
13 localization of all three ASO compounds with the receptor (Fig. 4A). Furthermore, SPR was
14 used to comparatively study the relative binding of the different chemistries to SCARA1. His-
15 tagged SCARA-1 receptors were immobilized on the chip using an anti-His-tag antibody.
16
17 Response units were calculated for specific binding after subtraction of non-specific binding to
18 the chip or the antibody. PPMO demonstrated the highest binding followed by tcDNA, while
19 2'OMe displayed minimal binding (Fig. 4B). It was evident that the chemistries that are able to
20 form nanoparticles demonstrated more efficient binding to the receptor, which is in accordance
21 with the mode of action of SRs.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 CONCLUSIONS

40 Our data shows that two potent ASOs, PPMO and tcDNA, have a higher propensity to self-
41 assemble into nanoparticles and better binding to SCARA1 compared to the less potent 2'OMe.
42 We hypothesize that nanoparticle assembly enhances ASO uptake based on the particle-
43 wrapping model for receptor-mediated uptake of nanoparticles^{45,46}. In this model, optimal
44 uptake requires a certain threshold of particle size. Below this threshold uptake will be impeded
45 by the high energy cost required for a high curvature of the membrane to wrap the particle, and
46 above it the uptake will be limited by the number of the receptors available for efficient particle
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 wrapping⁴⁷. An optimal radius for uptake has been predicted theoretically to be around 25-30
4
5 nm and has also been validated experimentally⁴⁸. Interestingly, TEM pictures show that both
6
7 PPMO and tcDNA¹³ nanoparticles are within this size range. Thus, the self-assembly process is
8
9 important for mediating this type of interaction through SRs. The importance of the self-
10
11 assembly process for uptake can be depicted in a model where single ASO molecules fail the
12
13 criteria required for passive uptake into cells due to charge and size restrictions (Lipinski rule of
14
15 5⁴⁹), however, they can gain access via receptor mediated endocytosis only if they reach a
16
17 certain size threshold (particle-wrapping model) (Fig. 5).
18
19
20

21
22 Unlike preformed synthetic nanoparticles, this process is spontaneous and dynamic, which
23
24 means that the particles form and deform under different conditions. However, the apparent high
25
26 propensity to self-assemble increases the probability of PPMO and tcDNA to form nanoparticles
27
28 in proximity to the cell surface compared to other chemistries. In this regard, PPMOs and tcDNA
29
30 resemble *in vivo* nanoparticle-based delivery systems and *in vitro* transfection reagents without
31
32 the need for exogenous delivery or complexing agents. Furthermore, the spontaneous and
33
34 reversible nature of the self-assembly process can explain the enhanced biodistribution of
35
36 PPMOs and tcDNAs to tissues that are inaccessible to conventional nanoparticles, like skeletal
37
38 muscle for example. While preformed nanoparticles are unable to extravasate into most tissues
39
40 except liver and spleen due to the size restriction of capillary fenestrations, we speculate that
41
42 self-assembling chemistries are able to extravasate through capillary fenestrations as single
43
44 molecules and reform nanoparticles upon accumulation and reaching high local concentrations *in*
45
46 *situ*. However, more *in vivo* pharmacokinetic and biodistribution studies are needed to elucidate
47
48 these mechanisms in more detail as a limitation of *in vitro* cell systems is that they differentially
49
50 express proteins on their surface when compared to *in vivo* conditions.
51
52
53
54
55
56
57
58
59
60

1
2
3 We believe that such models are crucial for understanding the pharmacokinetics and dynamics of
4 current ASO therapeutics for better design and development of new ASO chemistries and
5 delivery vehicles. Based on the findings discussed above, novel drug delivery platforms can be
6 designed to enhance the propensity of self-assembly or to target SCARAs. These findings also
7 highlight the importance of understanding the uptake mechanism for the clinical development of
8 ASOs and pave the way for successfully applying ASOs to the treatment of genetic diseases.
9
10
11
12
13
14
15
16
17
18
19

20 **METHODS**

21 **Antisense oligonucleotides (ASOs).**

22 All ASOs target the donor splice site of exon 23 of the mouse dystrophin pre-mRNA. The most
23 efficient sequence was chosen for all chemistries from previously reported studies. TcDNA-PS
24 (5'-AACCTCGGCTTACCT-3') was synthesized by SYNTHENA, Bern. 2'OMePS (5'-
25 GGCCAAACCUCGGCUUACCU-3') was synthesized by Integrated DNA Technologies (IDT,
26 USA) and PMO (5'-GGCCAAACCTCGGCTTACCTGAAAT-3') was ordered from Gene Tools
27 LLC. Conjugations of peptide (B-peptide: RXRRBRRXRRBRXB, Pip6a: RXRRBRRXR
28 YQFLI RXRBRXR, X, 6-aminohexanoic acid; B, b-alanine) with PMO were synthesized
29 through use of a stable amide linker as described elsewhere⁵⁰.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **DLS, TEM, CMC and zeta potential**

47 DLS measurements were performed on Viscotek 802 instrument (Malvern, USA) using 30 μ l of
48 1 mM ASO in PBS. DLS measurements in simulated physiologic conditions were performed by
49 mixing equal volumes of the ASOs with filtered albumin (BSA, Sigma-Aldrich, Germany)
50 solution in PBS (4.25 g/dL) at 37 °C for 1h then measuring on the DLS machine after appropriate
51
52
53
54
55
56
57
58
59
60

1
2
3 dilution (10x). For TEM visualization, PPMO was mounted on formvar/carbon coated 200 mesh
4
5 nickel grids (Agar Scientific, UK), then negatively stained using an aqueous solution of uranyl
6
7 acetate and visualized using a JEOL 1010 transmission electron microscope (JEOL, Peabody,
8
9 MA, USA) at 50,000 x magnification. For CMC measurements, eosin Y at a final concentration
10
11 of 0.019 mM was mixed with different concentrations of PPMO (50, 25, 15, 12, 10, 9, 8, 7, 6, 5,
12
13 4, 3, 2, 1, 0.5, 0.25, 0.125 μM). UV absorption was measured at 542 nm using Biotek Synergy
14
15 HT spectrophotometer (Biotek, USA). Zeta potential measurements were carried out on a
16
17 Zetasizer instrument (Malvern, USA). Charge reversal gel experiments were run on 1.25%
18
19 agarose gel with ethidium bromide using different buffers including: TAE, TBE, TBE with 4x
20
21 Tris and TBE with 4x boric acid and visualized using UV. For visualization nanoparticles in
22
23 serum, FITC-labelled ASOs were incubated in 100 μl of whole serum at a final concentration of
24
25 10 μM (Fetal Bovine Serum, Heat inactivated (FBS)) for 1 h at 37°C. After incubation, ASOs
26
27 were layered on top of a sucrose gradient. The gradient was composed of seven 1.25 ml fractions
28
29 of sucrose dissolved in PBS. The concentrations of the fractions from the top to the bottom were
30
31 15%-45% in 5% increments. Once layered, the gradients' interfaces were smoothed through
32
33 diffusion by vertical incubation at 4°C overnight. The loaded gradients were spun in an
34
35 ultracentrifuge (Beckman Coulter OptimaLE 80K) using a swinging bucket rotor (Beckman
36
37 Coulter, SW 41Ti) at 200000 xg for 4h at 4°C. The gradients were then retrieved and 1ml
38
39 fractions from top to bottom were collected (10 fractions in total per ASO). 100 μl per fraction
40
41 were transferred to a clear bottom black plate and screened for fluorescence signal. The fractions
42
43 with highest signal were loaded on a sandwiched coverslip-slide (two spacers made of double
44
45 sided tape were used to fix the coverslip on the slide) treated with 50 μl of a 5mg/mL BSA in
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 PBS solution for 10 minutes and subsequently imaged using an oil immersion 100x objective in
4
5
6 a Nikon Eclipse TE2000-U equipped with a Watec WAT-902H camera.
7
8
9

10 **Cell culture and PCR**

11
12 Murine C2C12 cells were grown in DMEM (Dulbecco's Modified Eagle Medium), high glucose,
13
14 GlutaMAX media (Life Technologies, USA) with 10% fetal bovine serum (FBS, Life
15
16 Technologies) and 1% penicillin/streptomycin (Life Technologies). Murine H2k *mdx* myoblasts
17
18 were cultured in gelatin (0.01%)-coated flasks at 33 °C, under 10% CO₂, in Dulbecco's modified
19
20 Eagles medium (DMEM PAA laboratories) supplemented with 20% heat-inactivated fetal bovine
21
22 serum (FBS Gold, PAA laboratories), 2% chicken embryo extract (Seralab), 1%
23
24 penicillin/streptomycin- neomycin antibiotic mixture (Life Technologies) and 3 pg/ml γ -
25
26 interferon (PeproTech). For differentiation cells (1×10^5) were seeded into wells of a 24-well
27
28 plate and the medium was changed after 24 h into differentiation medium consisting of DMEM
29
30 containing 2% horse serum (Life Technologies) and differentiated for 3-4 days before
31
32 experimentation. For PPMO treatment, cells were treated with a concentration of 500 nM in
33
34 serum-free Opti-MEM® medium for 4 h, the medium was then changed for differentiation
35
36 medium and incubation continued for a further 20 h. For RT-PCR detection of exon skipping,
37
38 cells were lysed and RNA harvested using RNeasy kit (Qiagen, Germany) and quantified, then
39
40 used for nested PCR procedure. Briefly, RNA was amplified on 2 steps with gene-specific
41
42 primers (Ex 20-26, Fwd: CAG AAT TCT GCC AAT TGC TGA G-, Rev: TTC TTC AGC TTG
43
44 TGT CAT CC) using Gene Amp PCR core kit (Life Technologies). Then cDNA was further
45
46 amplified using Amplitaq Gold polymerase (Life Technologies, USA) with primers: Ex 20-26:
47
48 Fwd: CCC AGT CTA CCA CCC TAT CAG AGC, Rev: CCT GCC TTT AAG GCT TCC TT).
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 PCR products were examined by electrophoresis on a 2% agarose gel. qPCR analysis was
4 performed on cDNA from C2C12 and H2k *mdx* cells using 25 ng cDNA template and amplified
5 with Taqman Gene Expression Master Mix (Applied Biosystems, Warrington, UK) on
6 a StepOne Plus Thermocycler (Applied Biosystems, Warrington, UK). Taqman probes
7 targeting SCARA1/3/4/5 (Life Technologies) were used and murine Glyceraldehyde 3-phosphate
8 dehydrogenase (GAPDH) probes were used as an internal control for cDNA levels.
9
10
11
12
13
14
15
16
17
18
19

20 **Scavenger receptor (SR) inhibition**

21 Differentiated C2C12 or H2k *mdx* (1×10^5) were treated with SR ligands and controls: fucoidin
22 sulfate, dextran sulfate, chondroitin sulfate, polyinosinic acid, polycytidylic acid (Sigma-Aldrich,
23 Germany) for 1 h before adding the ASOs. Cells were then treated with the ASOs and analyzed
24 as stated above. For siRNA treatment, C2C12 myoblasts differentiated for 24 h were treated
25 with either a cocktail of siRNAs, SACRA1,2,4 and 5, 25 nM each (siGenome SMART pool,
26 Dharmacon, USA) or scrambled control siRNA (100 nM) using Lipofectamine RNAiMax®
27 (Life Technologies) according to the manufacturer's protocol. After 24 h, medium was changed
28 and cells were treated with PPMO as explained earlier.
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Animal experiments**

44 Experiments were carried out in the Biomedical Sciences Unit, University of Oxford according
45 to procedures authorized by the UK Home Office. SCARA1 ^{-/-} and C57BL/6 mice (14 month
46 old, n = 4) were used. SCARA1 ^{-/-} mice were generated by Professor Tatsuhiko Kodama ²⁸, and a
47 colony has been maintained in our lab since then. Pip6-PMO conjugates were prepared in 0.9%
48 saline solution at a final dose of 10 mg/kg and administered via the tail vein. One week later
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 mice were sacrificed by CO₂ inhalation, and tissues harvested and snap-frozen in cooled
4
5 isopentane before storage at -80 °C. Total RNA was extracted from tissues using TRIzol reagent
6
7 (Life Technologies) following manufacturer's instructions. For quantitative analysis of exon
8
9 skipping levels, 1 µg of RNA was reverse transcribed using the High Capacity cDNA RT Kit
10
11 (Applied Biosystems, Warrington, UK) according to manufacturer's instructions. qPCR analysis
12
13 was performed using 25 ng cDNA template and amplified with Taqman Gene Expression Master
14
15 Mix (Applied Biosystems, Warrington, UK) on a StepOne Plus Thermocycler (Applied
16
17 Biosystems, Warrington, UK). Levels of *Dmd* exon 23 skipping was determined by multiplex
18
19 qPCR of FAM-labelled primers spanning Exon 20-21 (Assay Mm.PT.47.9564450, Integrated
20
21 DNA Technologies, Leuven, Belgium) and HEX-labelled primers spanning Exon 23-24
22
23 (Mm.PT.47.7668824, Integrated DNA Technologies). The percentage of *Dmd* transcripts
24
25 skipping exon 23 was determined by normalizing *Dmd* exon 23-24 amplification levels to *Dmd*
26
27 exon 20-21 levels.
28
29
30
31
32
33
34
35

36 **Fluorescence microscopy and spectrophotometry**

37
38 For immunofluorescence, cells were treated with either Cy5 conjugated PPMO⁵¹, or FITC
39
40 conjugated 2'OMePS or tcDNA oligonucleotides for 4 hours then washed 3 times with PBS plus
41
42 (PBS containing Ca²⁺ and Mg²⁺) solution, and fixed with methanol at -20° C for 10 minutes.
43
44 Cells were then washed and stored in PBS at 4° C for future immunofluorescence. For co-
45
46 localization, cells were treated with 0.1% Triton-X100 (Sigma-Aldrich) in PBS for 10 minutes,
47
48 and washed three times with PBS plus, then blocked with 1% bovine serum albumin (BSA,
49
50 Sigma Aldrich) containing PBS for 1 h. Cells were then incubated with rat anti-mouse SCARA1
51
52 (1:200 dilution, Bio-Rad, Hercules, CA), then washed three times with PBS plus and treated with
53
54
55
56
57
58
59
60

1
2
3 1:500 Alexa Fluor 488 goat anti-rat (Life Technologies) for 1 h. DAPI (1:5000 dilution, Sigma
4 Aldrich) staining was then completed for 2 minutes, after which cells were washed and mounted
5 with fluorescent mounting medium S3023 (Dako, Tokyo, Japan) onto glass slides. Visualization
6 was carried out on a Leica fluorescent microscope with pictures taken by Axiovision fluorescent
7 camera and Axiovision software (Zeiss, Oberkochen, Germany). Spectrophotometric
8 measurements for the uptake of FITC-labeled ASOs were performed in tissue-culture coated
9 black plates with clear optical bottom (Corning, USA) using Victor³ spectrophotometer (Perkin
10 Elmer, USA) 24 h after ASO addition.
11
12
13
14
15
16
17
18
19
20
21
22
23

24 **SPR**

25
26 Binding experiments were performed with a Biacore 3000 system (GE Healthcare) using CM5
27 chip. Anti-his-tag antibody was immobilized using amine coupling. Subsequently, His-tagged
28 recombinant mouse SR-AI (SCARA1) (R&D Systems, USA) receptor was immobilized on a
29 CM5 chip to give < 420 RU. For the binding assay, ASOs in PBS were injected at 10 μ L/min at
30 25 °C. Data traces were zeroed in the x and y axis after subtraction of non-specific binding.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1. Characterization self-assembling nanoparticles. (A) DLS analysis of tcDNA, 2'OMe and PPMO. Each was measured 3 times (different colors) at 1 mM concentration in PBS showing the profile of the different populations present. (B) Negatively stained TEM pictures of nanoparticles formed by PPMO; Bar = 100 nm. (C) Critical micelle concentration (CMC) determination of PPMO using the dye micellization method (absorbance at 542 nm). Eosin Y concentration: 0.019 mM. The X-axis represents log the concentration in nM. CMC is the inverse log of the point at the intersection between the linear portion of the curve near the inflection point ($R^2=0.924$) and the absorbance of the dye in the absence of any surfactant represented by the horizontal line. CMC = 1380.38 nM. (D) PPMO at different concentrations was loaded on a 1.25% agarose gel using TAE as running buffer.

Figure 2. Involvement of SCARA in PPMO uptake. (A) Differentiated C2C12 cells (1×10^5) were pretreated SR ligands and control (fucoidin sulfate, dextran sulfate and chondroitin sulfate) at 50 $\mu\text{g/ml}$ for 1 h then treated with PPMO (500 nM) for 4 h in Opti-MEM® before changing the medium to differentiation medium and incubation for 20 h. The products of nested reverse transcription-PCR (RT-PCR) were examined by electrophoresis on a 2% agarose gel. The top band indicates full-length transcript and the bottom band represents exon-skipped transcript (B) C2C12 myoblasts differentiated for 1 d, then treated with either siRNA cocktail targeting SACRA1,2,4 and 5 (25 nM each) using Lipofectamine RNAiMax® or scrambled control siRNA (Cntrl. siRNA, 100 nM). After 24 h, medium was changed and cells treated with PPMO (500 nm) as stated above. The products of nested RT-PCR were examined by gel electrophoresis and the percent of exon skipping was calculated using densitometry. (C) Quantitative PCR (qPCR)

1
2
3 analysis of dystrophin exon 23-skipping in tibialis anterior muscle (TA), diaphragm and heart 1
4 week following intravenous injection of 10 mg/kg PPMO (Pi6a-PMO) in adult SCARA1^{-/-} and
5 wild-type (WT) C57 BL/6 mice (n=4). The percentage of exon 23-skipping of the *Dmd*
6 transcripts was determined by normalizing exon 23-24 amplification levels to exon 20-21 levels.
7
8 *P < 0.05; Student's t-test; error bars represent mean ± SEM.
9
10
11
12
13
14
15
16
17

18 **Figure 3. Role of SRs in the uptake of tcDNA and 2'OMe.** (A) Differentiated C2C12 cells
19 (2.5x10⁴/cm²) were pretreated with SR ligands including fucoidin sulfate or polyinosinic acid
20 (poly I), and controls including chondroitin sulfate or polycytidylic acid (poly C), at 100 µg/ml
21 for 1 h. Then cells were incubated with FITC-2'OMePS (200 nM) or FITC-tcDNA (200 nM) for
22 4 h and visualized by fluorescence microscopy. Scale bar, 20 µm. (B) Quantitative fluorescence
23 image analysis, mean fluorescence intensity was quantified using ImageJ software. *P < 0.05,
24 **P < 0.01, ***P < 0.001; one-way ANOVA, error bars represent mean ± SEM.
25
26
27
28
29
30
31
32
33
34
35

36 **Figure 4. Interaction with SCARA1.** (A) Representative images of the cellular co-localization
37 of Cy5-PPMO or FITC-2'OMePS and FITC-tcDNA with rat anti-mouse SCARA1 antibody in
38 differentiated C2C12 myotubes at 4 h as measured by fluorescence microscopy (Cy5- PPMO,
39 FITC-tcDNA and FITC- 2'OMePS were used at 200, 500 and 500 nM, respectively). Scale bar,
40 20 µm. (B) Binding experiments were performed using a Biacore 3000 system. His-tagged
41 SCARA1 receptor was immobilized on the chip using an anti-his-tag antibody to give < 420 RU.
42 Different ASOs in PBS were injected at 10 µL/min at 25 °C. Data traces were zeroed in the x and
43 y axis after subtraction of non-specific binding.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 5: An illustration describing the relation between two different models of cellular**
4 **uptake.** Singular molecules follow the Lipinski rule of 5⁴⁹ (molecular weight is less than 500
5
6 Da, lipophilicity-expressed as is less than 5, the number of hydrogen bond donators is less than
7
8 5 and the number of hydrogen bond acceptors is less than 10). This leads to sharp decrease in
9
10 uptake with increasing size and charge of a molecule. That is why singular naked ASOs fail to
11
12 cross cell-membranes. However, when they reach certain size, either by self-assembly or
13
14 incorporation into nanoparticle-based delivery vectors, they lie within the scope of the receptor-
15
16 mediated uptake process, especially through pattern recognition receptors of the innate immune
17
18 system such as scavenger receptors. For this process to take place the nanoparticles have to
19
20 possess a minimum radius (r_{minimum} , around 22 nm)⁴⁵. Beyond an upper limit (r_{maximum} , around 60
21
22 nm) uptake starts to drop once more. Below the minimum radius, uptake is impeded by the high
23
24 energy cost required for high curvature of the membrane for particle wrapping, and above the
25
26 maximum radius uptake will be limited by the number of the receptors available for efficient
27
28 particle interaction⁴⁷.
29
30
31
32
33
34
35
36
37
38

39 **Conflict of Interest**

40
41 The authors declare no competing financial interest.
42
43
44

45 **Acknowledgements**

46
47 Work in the laboratory of MJG was supported by the Medical Research Council (MRC
48
49 programme number U105178803). SELA is supported by Swedish Medical Research Council
50
51 (VR-Med and EuroNanoMED2) and the Swedish Society of Medical Research (SSMF). AGC
52
53 was supported by the European Commission under the Seventh Framework Programme (FP7), as
54
55
56
57
58
59
60

1
2
3 part of the Marie Curie Initial Training Network, EScoDNA (GA no. 317110). We would like to
4
5 thank Dr. David Staunton at the Biophysical Instrumentation Facility, Department of
6
7 Biochemistry and Mr. Marcus Bridge at the Dunn School of Pathology for help with
8
9 physicochemical characterization and SPR.
10
11

12
13
14
15 Supporting Information Available: [Self-assembly into nanoparticles is essential for receptor
16 mediated uptake of therapeutic antisense oligonucleotides.] This material is available free of
17 charge via the Internet at <http://pubs.acs.org>.
18
19
20

21 22 23 24 **References**

- 25
26
27 1. Kole, R.; Krainer, A. R.; Altman, S. *Nat. Rev. Drug Discov.* **2012**, *11*, 125-140.
28
29
30 2. Wood, M. J.; Gait, M. J.; Yin, H. *Brain.* **2010**, *133*, 957-972.
31
32
33 3. Koo, T.; Wood, M. J. *Hum. Gene Ther.* **2013**, *24*, 479-488.
34
35
36 4. Douglas, A. G.; Wood, M. J. *Mol. Cell. Neurosci.* **2013**, *56*, 169-185.
37
38
39 5. Deleavey, G. F.; Damha, M. J. *Chem. Biol.* **2012**, *19*, 937-954.
40
41
42 6. Mastrobattista, E.; van der Aa, M. A.; Hennink, W. E.; Crommelin, D. J. *Nat. Rev. Drug*
43
44
45
46
47 *Discov.* **2006**, *5*, 115-121.
48
49
50 7. Soifer, H. S.; Koch, T.; Lai, J.; Hansen, B.; Hoeg, A.; Oerum, H.; Stein, C. A. *Methods Mol.*
51
52
53
54
55
56
57
58
59
60 *Biol.* **2012**, *815*, 333-346.


- 1
2
3 8. El Andaloussi, S. A.; Hammond, S. M.; Mager, I.; Wood, M. J. *Curr. Gene Ther.* **2012**, *12*,
4 161-178.
5
6
7
8
9 9. Yin, H.; Moulton, H. M.; Seow, Y.; Boyd, C.; Boutilier, J.; Iverson, P.; Wood, M. J. *Hum.*
10 *Mol. Genet.* **2008**, *17*, 3909-3918.
11
12
13
14 10. Leumann, C. J. *Nucleic Acids Symp. Ser. (Oxf)* **2006**, 55-56.
15
16
17
18 11. Murray, S.; Ittig, D.; Koller, E.; Berdeja, A.; Chappell, A.; Prakash, T. P.; Norrbom, M.;
19 Swayze, E. E.; Leumann, C. J.; Seth, P. P. *Nucleic Acids Res.* **2012**, *40*, 6135-6143.
20
21
22
23 12. Yin, H.; Moulton, H. M.; Betts, C.; Merritt, T.; Seow, Y.; Ashraf, S.; Wang, Q.; Boutilier, J.;
24 Wood, M. J. *Mol. Ther.* **2010**, *18*, 1822-1829.
25
26
27
28
29
30 13. Goyenvalle, A.; Griffith, G.; Babbs, A.; Andaloussi, S. E.; Ezzat, K.; Avril, A.; Dugovic, B.;
31 Chaussonot, R.; Ferry, A.; Voit, T.; Amthor, H.; Buhr, C.; Schurch, S.; Wood, M. J.; Davies,
32 K. E.; Vaillend, C.; Leumann, C.; Garcia, L. *Nat. Med.* **2015**.
33
34
35
36
37
38 14. Ezzat, K.; Helmfors, H.; Tudoran, O.; Juks, C.; Lindberg, S.; Padari, K.; El Andaloussi, S.;
39 Pooga, M.; Langel, Ü. *FASEB J.* **2012**, *3*, 1172-80.
40
41
42
43
44 15. Canton, J.; Neculai, D.; Grinstein, S. Scavenger receptors in homeostasis and immunity. *Nat.*
45 *Rev. Immunol.* **2013**, *13*, 621-634.
46
47
48
49
50 16. Platt, N.; Gordon, S. *Chem. Biol.* **1998**, *5*, R193-203.
51
52
53
54 17. Pluddemann, A.; Neyen, C.; Gordon, S. *Methods* **2007**, *43*, 207-217.
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
18. Arnida; Janat-Amsbury, M. M.; Ray, A.; Peterson, C. M.; Ghandehari, H. *Eur. J. Pharm. Biopharm.* **2011**, *77*, 417-423.
19. DeWitte-Orr, S. J.; Collins, S. E.; Bauer, C. M.; Bowdish, D. M.; Mossman, K. L. *PLoS Pathog.* **2010**, *6*, e1000829.
20. Bowdish, D. M.; Gordon, S. *Immunol. Rev.* **2009**, *227*, 19-31.
21. Zaias, J.; Mineau, M.; Cray, C.; Yoon, D.; Altman, N. H. *J. Am. Assoc. Lab. Anim. Sci.* **2009**, *48*, 387-390.
22. Cheng, C. J.; Saltzman, W. M.; Slack, F. J. *Curr. Med. Chem.* **2013**, *20*, 3582-3593.
23. Patist, A, Bhagwat, S S, Penfield, K W, Aikens, P, Shah, D O. *J Surfactants Deterg.* **2000**, *3*, 53-58.
24. Ge, W.; Kesselman, E.; Talmon, Y.; Hart, D. J.; Zakin, J. L. *J. Non Newtonian Fluid Mech.* **2008**, *154*, 1-12.
25. Aoki, Y.; Nagata, T.; Yokota, T.; Nakamura, A.; Wood, M. J.; Partridge, T.; Takeda, S. *Hum. Mol. Genet.* **2013**, *22*, 4914-4928.
26. Lehto, T.; Castillo Alvarez, A.; Gauck, S.; Gait, M. J.; Coursindel, T.; Wood, M. J.; Lebleu, B.; Boisguerin, P. *Nucleic Acids Res.* **2014**, *42*, 3207-3217.
27. Betts, C.; Saleh, A. F.; Arzumanov, A. A.; Hammond, S. M.; Godfrey, C.; Coursindel, T.; Gait, M. J.; Wood, M. J. *Mol. Ther. Nucleic Acids.* **2012**, *1*, e38.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28. Suzuki, H.; Kurihara, Y.; Takeya, M.; Kamada, N.; Kataoka, M.; Jishage, K.; Ueda, O.; Sakaguchi, H.; Higashi, T.; Suzuki, T.; Takashima, Y.; Kawabe, Y.; Cynshi, O.; Wada, Y.; Honda, M.; Kurihara, H.; Aburatani, H.; Doi, T.; Matsumoto, A.; Azuma, S.; Noda, T.; Toyoda, Y.; Itakura, H.; Yazaki, Y.; Kodama, T. *Nature*. **1997**, *386*, 292-296.
29. Pujals, S.; Fernandez-Carneado, J.; Lopez-Iglesias, C.; Kogan, M. J.; Giralt, E. *Biochim. Biophys. Acta* **2006**, *1758*, 264-279.
30. Kohno, M.; Horibe, T.; Ohara, K.; Ito, S.; Kawakami, K. *Chem. Biol.* **2014**, *21*, 1522-1532.
31. Kondo, E.; Saito, K.; Tashiro, Y.; Kamide, K.; Uno, S.; Furuya, T.; Mashita, M.; Nakajima, K.; Tsumuraya, T.; Kobayashi, N.; Nishibori, M.; Tanimoto, M.; Matsushita, M. *Nat. Commun.* **2012**, *3*, 951.
32. Peiser, L.; Gordon, S. *Microbes Infect.* **2001**, *3*, 149-159.
33. Zhou, H.; Liao, J.; Aloor, J.; Nie, H.; Wilson, B. C.; Fessler, M. B.; Gao, H. M.; Hong, J. S. *J. Immunol.* **2013**, *190*, 115-125.
34. Bates, P. J.; Kahlon, J. B.; Thomas, S. D.; Trent, J. O.; Miller, D. M. *J. Biol. Chem.* **1999**, *274*, 26369-26377.
35. Burge, S.; Parkinson, G. N.; Hazel, P.; Todd, A. K.; Neidle, S. *Nucleic Acids Res.* **2006**, *34*, 5402-5415.

- 1
2
3 36. Bijsterbosch, M. K.; Manoharan, M.; Rump, E. T.; De Vruueh, R. L.; van Veghel, R.; Tivel,
4
5 K. L.; Biessen, E. A.; Bennett, C. F.; Cook, P. D.; van Berkel, T. J. *Nucleic Acids Res.* **1997**,
6
7 25, 3290-3296.
8
9
10
11 37. Biessen, E. A.; Vietsch, H.; Kuiper, J.; Bijsterbosch, M. K.; Berkel, T. J. *Mol. Pharmacol.*
12
13 **1998**, 53, 262-269.
14
15
16
17 38. de Diesbach, P.; N'Kuli, F.; Berens, C.; Sonveaux, E.; Monsigny, M.; Roche, A. C.; Courtoy,
18
19 P. J. *Nucleic Acids Res.* **2002**, 30, 1512-1521.
20
21
22
23 39. Sawai, K.; Mahato, R. I.; Oka, Y.; Takakura, Y.; Hashida, M. *J. Pharmacol. Exp. Ther.* **1996**,
24
25 279, 284-290.
26
27
28
29 40. Benimetskaya, L.; Berton, M.; Kolbanovsky, A.; Benimetsky, S.; Stein, C. A. *Nucleic Acids*
30
31 *Res.* **1997**, 25, 2648-2656.
32
33
34
35 41. Wu, C. C.; Castro, J. E.; Motta, M.; Cottam, H. B.; Kyburz, D.; Kipps, T. J.; Corr, M.;
36
37 Carson, D. A. *Hum. Gene Ther.* **2003**, 14, 849-860.
38
39
40
41 42. Bishop, J. S.; Guy-Caffey, J. K.; Ojwang, J. O.; Smith, S. R.; Hogan, M. E.; Cossum, P. A.;
42
43 Rando, R. F.; Chaudhary, N. *J. Biol. Chem.* **1996**, 271, 5698-5703.
44
45
46
47 43. Suzuki, K.; Doi, T.; Imanishi, T.; Kodama, T.; Tanaka, T. *Eur. J. Biochem.* **1999**, 260, 855-
48
49 860.
50
51
52
53 44. Pearson, A. M.; Rich, A.; Krieger, M. *J. Biol. Chem.* **1993**, 268, 3546-3554.
54
55
56
57 45. Gao, H.; Shi, W.; Freund, L. B. *Proc. Natl. Acad. Sci. U. S. A.* **2005**, 102, 9469-9474.
58
59

- 1
2
3 46. Nel, A. E.; Madler, L.; Velegol, D.; Xia, T.; Hoek, E. M.; Somasundaran, P.; Klaessig, F.;
4
5 Castranova, V.; Thompson, M. *Nat. Mater.* **2009**, *8*, 543-557.
6
7
8
9 47. Shi, W.; Wang, J.; Fan, X.; Gao, H. *Phys. Rev. E. Stat. Nonlin Soft Matter Phys.* **2008**, *78*,
10
11 061914.
12
13
14
15 48. Jiang, W.; Kim, B. Y.; Rutka, J. T.; Chan, W. C. *Nat. Nanotechnol.* **2008**, *3*, 145-150.
16
17
18
19 49. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. *Adv. Drug Deliv. Rev.* **2001**, *46*,
20
21 3-26.
22
23
24
25 50. Wu, R. P.; Youngblood, D. S.; Hassinger, J. N.; Lovejoy, C. E.; Nelson, M. H.; Iversen, P.
26
27 L.; Moulton, H. M. *Nucleic Acids Res.* **2007**, *35*, 5182-5191.
28
29
30
31 51. Shabanpoor, F.; Gait, M. J. *Chem. Commun. (Camb)* **2013**, *49*, 10260-10262.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



34x21mm (300 x 300 DPI)

Nano Letters








Figure 2.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43





Figure 4.

Nano Letters

